Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02469077 · ClinicalTrials.gov registry record · NA
Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function
A NA study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 117
- Enrollment target
NCT02469077 is a NA study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 117 participants.
The verdict
NCT02469077, a NA study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 117 participants
- Enrollment target
Study Summary
Chronic Pain (CP) management has increasingly utilized long-term opioid analgesic therapy, a change associated with increased opioid abuse (via greater exposure in vulnerable individuals), non-pain health consequences (hormone changes, falls), and a dramatic rise in opioid-related overdoses and deaths. Treatment strategies that minimize the need for chronic high-dose opioids are sorely needed. This project will test the novel hypothesis that effective pain relief can be achieved at lower opioid analgesic doses by increasing levels of endogenous opioids (EOs).
Interventions
- DRUG Placebo
- DRUG Morphine
- DRUG naloxone
- BEHAVIORAL 6 week aerobic exercise intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2015-08 |
| Est. Completion | 2019-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02469077
The ClinicalTrials.gov registry entry for NCT02469077 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02469077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02469077 about?
NCT02469077 is a clinical study titled "Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function". Chronic Pain (CP) management has increasingly utilized long-term opioid analgesic therapy, a change associated with increased opioid abuse (via greater exposure in vulnerable individuals), non-pain health consequences (hormone changes, falls), and a dramatic rise in opioid-related overdoses and deat...
What is the current status of trial NCT02469077?
This trial is currently completed. It is a NA study. The enrollment target is 117 participants. The study started on 2015-08. Estimated completion is 2019-09.
What interventions are being tested in trial NCT02469077?
The interventions under investigation include: Placebo (DRUG), Morphine (DRUG), naloxone (DRUG), 6 week aerobic exercise intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT02469077?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.